Limits...
Impact of epoetin beta on quality of life in patients with malignant disease.

Boogaerts M, Coiffier B, Kainz C, Epoetin beta QOL Working Gro - Br. J. Cancer (2003)

Bottom Line: Baseline to final visit changes in SF-36 PCS, FACT-F and VAS scores were significantly greater with epoetin beta than with standard care (P<0.05); changes in FACT-An subscale score tended to be greater with epoetin beta (P=0.076).Epoetin beta significantly increased Hb concentrations relative to standard care (responders: 47% vs 13%; P<0.001).Levels of endogenous erythropoietin <50 mIU ml(-1) were significantly predictive of response (OR 2.496, 95% CI: 1.21-5.13).

View Article: PubMed Central - PubMed

Affiliation: Labo Hematologie Transplant, U.Z. Gasthuisberg, Leuven, Belgium. Marc.Boogaerts@med.kuleuven.ac.be

ABSTRACT
This open-label, prospective study was conducted to compare the impact of epoetin beta vs standard care on quality of life (QoL) in anaemic patients with lymphoid or solid tumour malignancies. A total of 262 anaemic patients (haemoglobin [Hb]or=2 g dl(-1) increase in Hb level without need of transfusion after the initial 4 weeks of treatment. Baseline to final visit changes in SF-36 PCS, FACT-F and VAS scores were significantly greater with epoetin beta than with standard care (P<0.05); changes in FACT-An subscale score tended to be greater with epoetin beta (P=0.076). Epoetin beta significantly increased Hb concentrations relative to standard care (responders: 47% vs 13%; P<0.001). Levels of endogenous erythropoietin <50 mIU ml(-1) were significantly predictive of response (OR 2.496, 95% CI: 1.21-5.13). Epoetin beta therapy significantly improves QoL compared with standard care in anaemic patients with solid tumours and lymphoid malignancies.

Show MeSH

Related in: MedlinePlus

Median increase in haemoglobin levels in response to epoetin β (n=133) or standard care (n=129) at the end of the study period.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376376&req=5

fig4: Median increase in haemoglobin levels in response to epoetin β (n=133) or standard care (n=129) at the end of the study period.

Mentions: Change in median haemoglobin levels in response to epoetin β (n=133) or standard care (n=129) during the study period.


Impact of epoetin beta on quality of life in patients with malignant disease.

Boogaerts M, Coiffier B, Kainz C, Epoetin beta QOL Working Gro - Br. J. Cancer (2003)

Median increase in haemoglobin levels in response to epoetin β (n=133) or standard care (n=129) at the end of the study period.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376376&req=5

fig4: Median increase in haemoglobin levels in response to epoetin β (n=133) or standard care (n=129) at the end of the study period.
Mentions: Change in median haemoglobin levels in response to epoetin β (n=133) or standard care (n=129) during the study period.

Bottom Line: Baseline to final visit changes in SF-36 PCS, FACT-F and VAS scores were significantly greater with epoetin beta than with standard care (P<0.05); changes in FACT-An subscale score tended to be greater with epoetin beta (P=0.076).Epoetin beta significantly increased Hb concentrations relative to standard care (responders: 47% vs 13%; P<0.001).Levels of endogenous erythropoietin <50 mIU ml(-1) were significantly predictive of response (OR 2.496, 95% CI: 1.21-5.13).

View Article: PubMed Central - PubMed

Affiliation: Labo Hematologie Transplant, U.Z. Gasthuisberg, Leuven, Belgium. Marc.Boogaerts@med.kuleuven.ac.be

ABSTRACT
This open-label, prospective study was conducted to compare the impact of epoetin beta vs standard care on quality of life (QoL) in anaemic patients with lymphoid or solid tumour malignancies. A total of 262 anaemic patients (haemoglobin [Hb]or=2 g dl(-1) increase in Hb level without need of transfusion after the initial 4 weeks of treatment. Baseline to final visit changes in SF-36 PCS, FACT-F and VAS scores were significantly greater with epoetin beta than with standard care (P<0.05); changes in FACT-An subscale score tended to be greater with epoetin beta (P=0.076). Epoetin beta significantly increased Hb concentrations relative to standard care (responders: 47% vs 13%; P<0.001). Levels of endogenous erythropoietin <50 mIU ml(-1) were significantly predictive of response (OR 2.496, 95% CI: 1.21-5.13). Epoetin beta therapy significantly improves QoL compared with standard care in anaemic patients with solid tumours and lymphoid malignancies.

Show MeSH
Related in: MedlinePlus